CIK 0001658551 · Non-accelerated filer<br>Smaller reporting company
Amylyx Pharmaceuticals, Inc.
Sign in to watch- Ticker
- AMLX
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 464600503
- Phone
- 617-682-0917
- Business address
- 55 CAMBRIDGE PARKWAY, SUITE 6W, CAMBRIDGE, MA, 02142
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $10,951,125
- in 9 filings, $8.0M under 10b5-1 plans
Net −$10,951,125. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
- Cohen Joshua B −$4.0M Co-Chief Executive Officer sold 4% of stake
- Klee Justin B. −$4.0M Co-Chief Executive Officer sold 4% of stake
- FRATES JAMES M −$1.6M Chief Financial Officer sold 18% of stake
- MILNE GEORGE M JR −$831K Director sold 4% of stake
- Bedrosian Camille L −$325K Chief Medical Officer sold 3% of stake
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2024-02-26 | Cohen Joshua B Co-Chief Executive Officer | Grant or award | +126,667 | 3,027,137 | ||
| 2024-02-26 | Cohen Joshua B Co-Chief Executive Officer | Grant or award · Stock Option (right to buy) | +190,000 | 190,000 | ||
| 2024-02-26 | Klee Justin B. Co-Chief Executive Officer | Grant or award | +126,667 | 2,963,443 | ||
| 2024-02-26 | Klee Justin B. Co-Chief Executive Officer | Grant or award · Stock Option (right to buy) | +190,000 | 190,000 | ||
| 2024-02-26 | Mazzariello Gina Chief Legal Officer | Grant or award | +36,667 | 82,912 | ||
| 2024-02-26 | Mazzariello Gina Chief Legal Officer | Grant or award · Stock Option (right to buy) | +55,000 | 55,000 | ||
| 2024-02-23 | Mazzariello Gina Chief Legal Officer | Sale | −2,838 | $18.76 | $53K | 46,245 |
| 2024-01-25 | MILNE GEORGE M JR Director | Gift | −9,100 | 758,571 | ||
| 2024-01-16 | MILNE GEORGE M JR Director | Gift | −94,350 | 767,671 | ||
| 2024-01-09 | Klee Justin B. Co-Chief Executive Officer | Sale | −5,841 | $16.33 | $95K | 2,836,776 |
| 2024-01-09 | FRATES JAMES M Chief Financial Officer | Sale | −2,716 | $16.33 | $44K | 112,035 |
| 2024-01-09 | Cohen Joshua B Co-Chief Executive Officer | Sale | −5,841 | $16.33 | $95K | 2,900,470 |
| 2024-01-09 | Yeramian Patrick D Chief Medical Officer | Sale | −2,812 | $16.33 | $46K | 205,605 |
| 2023-12-27 | Olinger Margaret Chief Commercial Officer | Option exercise | +25,000 | $0.37 | $9K | 276,108 |
| 2023-12-27 | Olinger Margaret Chief Commercial Officer | Option exercise · Stock Option (Right to Buy) | −25,000 | 44,577 | ||
| 2023-12-15 | Firestone Karen Director | Purchase | +4,000 | $14.97 | $60K | 5,000 |
| 2023-11-27 | Bedrosian Camille L Chief Medical Officer | Grant or award | +58,333 | 58,333 | ||
| 2023-11-27 | Bedrosian Camille L Chief Medical Officer | Grant or award · Stock Option (Right to Buy) | +162,500 | 162,500 | ||
| 2023-11-16 | Cohen Joshua B Co-Chief Executive Officer | Option exercise | +63,694 | $1.57 | $100K | 2,906,311 |
| 2023-11-16 | Cohen Joshua B Co-Chief Executive Officer | Option exercise · Stock Option (Right to Buy) | −63,694 | 36,306 |
Page 9 of 19 · 362 trades